- Drug Class
- Calcium Channel Blocker (Dihydropyridine)
- Mechanism of Action (MOA)
- Blocks L-type Ca²⁺ channels in vascular smooth muscle → arterial vasodilation → ↓ afterload.
- Clinical Notes
- First-line HTN and vasospastic angina. Dose-dependent peripheral edema; minimal cardiac depression vs non-DHP.
Sources
Reviewed September 2026- FDA label — FDA / DailyMed
Checked against the guideline or standard reference the exam keys to. If it has moved, use Report an error below.
All pharmacology